PET Radiopharmaceuticals market is segmented by Type and by Application. Players, stakeholders, and other participants in the global PET Radiopharmaceuticals market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
F-18
Ru-82
Others
Segment by Application
Oncology
Cardiology
Neurology
Others
By Company
Cardinal Health Inc. (U.S.)
Mallinckrodt plc (Ireland)
GE Healthcare (U.K.)
Lantheus Medical Imaging, Inc. (U.S.)
Bayer AG (Germany)
Bracco Imaging S.p.A (Italy)
Eczacibasi-Monrol Nuclear Products (Turkey)
Nordion, Inc. (Canada)
Advanced Accelerator Applications S.A. (France)
IBA Molecular Imaging (Belgium)
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
